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Abstract
To develop sero-diagnostic markers for lung cancer, we generated monoclonal antibodies using pulmonary
adenocarcinoma (AD)-derived A549 cells as antigens by employing the random immunization method. Hybridoma
supernatants were immunohistochemically screened for antibodies with AMeX-fixed and paraffin-embedded A549 cell
preparations. Positive clones were monocloned twice through limiting dilutions. From the obtained monoclonal antibodies,
we selected an antibody designated as KU-Lu-5 which showed intense membrane staining of A549 cells. Based on
immunoprecipitation and MADLI TOF/TOF-MS analysis, this antibody was recognized as carbonic anhydrase XII (CAXII). To
evaluate the utility of this antibody as a sero-diagnostic marker for lung cancer, we performed dot blot analysis with a
training set consisting of sera from 70 lung cancer patients and 30 healthy controls. The CAXII expression levels were
significantly higher in lung cancer patients than in healthy controls in the training set (P,0.0001), and the area under the
curve of ROC was 0.794, with 70.0% specificity and 82.9% sensitivity. In lung cancers, expression levels of CAXII were
significantly higher in patients with squamous cell carcinoma (SCC) than with AD (P=0.035). Furthermore, CAXII was
significantly higher in well- and moderately differentiated SCCs than in poorly differentiated ones (P=0.027). To further
confirm the utility of serum CAXII levels as a sero-diagnostic marker, an additional set consisting of sera from 26 lung cancer
patients and 30 healthy controls was also investigated by dot blot analysis as a validation study. Serum CAXII levels were
also significantly higher in lung cancer patients than in healthy controls in the validation set (P=0.030). Thus, the serum
CAXII levels should be applicable markers discriminating lung cancer patients from healthy controls. To our knowledge, this
is the first report providing evidence that CAXII may be a novel sero-diagnostic marker for lung cancer.
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Introduction
Lung cancer is the leading cause of cancer death, comprising
13% (1.6 million) of the total cancer cases and 18% (1.4 million) of
the cancer deaths in the world in 2008 [1,2].
Tumor markers have been detected in sera, urine, and tissues
from patients with malignant tumors, and can be used for an
exact diagnosis, discrimination of benign or malignant tumors,
follow-up after therapies, and prediction of the patient’s outcome.
At present, some sero-diagnostic markers are used for lung
cancer, such as carcinoembryonic antigen (CEA) and sialyl Lewis
X antigen (SLX) for adenocarcinoma (AD), and cytokeratin 19
fragment (CYFRA) and squamous cell carcinoma antigen (SCCa)
for squamous cell carcinoma (SCC) [3]. The positive rates of
CEA, SLX, CYFRA, and SCCa are reportedly 57, 40,50,
50,60, and 60,80%, respectively. However, it has been
reported that these markers do not show sufficient tumor or
organ specificities; for example, SLX can show false-positive
results in the presence of pulmonary tuberculosis and pulmonary
fibrosis, and CYFRA can elevate with interstitial pneumonia and
renal failure.
Antibodies are usually developed using purified proteins or
synthetic peptides. We have exhaustively generated monoclonal
antibodies (MoAbs) against various tumor-associated proteins
using the pulmonary AD-derived A549 cell as an antigen with
the random immunization method [4], and over 1,000 MoAbs
have been obtained [5]. This method is expected to generate
antibodies against proteins with tumor-specific post-translational
modifications, which are difficult to obtain by conventional
immunization methods.
Carbonic anhydrase XII is a transmembrane zinc metalloen-
zyme that catalyzes the reversible hydration of carbon dioxide to
form bicarbonate (H2O+CO2uH
++HCO3
2), and is a member of
the alpha carbonic anhydrase (CA) family. CAXII has been
proposed to be involved in the acidification of the extracellular
microenvironment, which is suitable for rapid tumor growth.
CAXII overexpression was initially detected in renal cell
carcinoma, and subsequent studies confirmed its expression in
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pancreatic, and ovarian carcinoma, as well as in non-small cell
lung cancer (NSCLC) [6–11]. Its expression was influenced both
by factors related to differentiation and hypoxia in breast cancer in
vivo, and was associated with a more favorable prognosis in
invasive breast carcinoma patients [12]. Higher CAXII expression
was also correlated with a better overall and disease-specific
survival in patients with resectable NSCLC [13]. However, no
study has clarified CAXII in sera and its clinical utility as a sero-
diagnostic marker for patients with malignant tumors.
In this study, the specificity of the obtained anti-CAXII antibody
was confirmed by immunohistochemistry (IHC) and immunoblot-
ting with lung cancer cell lines and lung cancer tissues. To further
confirm its utility as a sero-diagnostic marker, CAXII levels in sera
from patients with lung cancer were studied by dot blot analysis.
Materials and Methods
1. Cell lines
The A549 and LC-2/ad cells derived from lung AD were
purchased from the Japanese Cancer Research Resources Bank
(Tokyo, Japan) and RIKEN BioResource Center (Ibaraki, Japan),
respectively. The RERF-LC-AI cells derived from lung SCC was
purchased from the RIKEN BioResource Center. The N231 cells
derived from SCLC were purchased from the American Type
Culture Collection (Rockville, MD, USA). LCN1, a large cell
neuroendocrine carcinoma (LCNEC) line, was established in our
laboratory [14]. These cells were grown in RPMI-1640 medium
(SIGMA, Steinheim, Germany) supplemented with 10% fetal
bovine serum (FBS; Biowest, Miami, FL, USA), 100 units/ml of
penicillin, and 100 mg/ml of streptomycin (GIBCO, Auckland,
New Zealand). After harvesting and washing twice with phosphate-
buffered saline without divalent ions(PBS-), sub-confluent cells were
stored at 280uC for proteomics analysis or fixed in 10% formalin
and embedded in paraffin for immunohistochemistry. A549 cells
were also AMeX-fixed [15] for immunohistochemical screening.
The SP2/O-Ag14 cells derived from a mouse myeloma were
purchased from the RIKEN BioResource Center, and were grown
in RPMI-1640 medium supplemented with 168-azaguanine (506
Hybri-Max, SIGMA), 10% FBS, penicillin, and streptomycin.
2. Ethics statement
All samples were collected in accordance with the ethical
guidelines and written consent mandated, and this study was
approved by the Ethics Committee of Kitasato University School
of Medicine. All patients and healthy controls were approached
based on approved ethical guidelines, and those who agreed to
participate in this study were required to sign consent forms.
Patients could refuse entry and discontinue participation at any
time. All participants provided written consent.
2.1. Sera. Sera from 70 patients with lung cancer (AD: 29,
SCC: 21, SCLC: 17, and LCNEC: 3) and 30 healthy controls were
used in the training set. In addition, a validation set consisting of
sera from 26 patients with lung cancer (AD: 20, SCLC: 5, and
LCNEC: 1) and 30 healthy controls was also studied. The
clinicopathological characteristics of the patients data are
summarized in Table 1.
Patient sera were collected at Kitasato University Hospital, and
healthy control sera were provided by Kyowa Medex Co., Ltd.
(Tokyo, Japan) and kept at 280uC until use.
3. Generation of monoclonal antibodies
A549 cell lysate was prepared with PBS(-) using an ultra-sonic
homogenizer (UH-50; SMT Company, Tokyo, Japan). Five-week-
old female BALB/c mice were immunized intra-peritoneally with
50 mg wet- weight of A549 cell lysate in 500 ml of PBS(-) 3 times
with a two-week interval. The antibody titer was tested by IHC
using 100-times diluted sera from the immunized mice as the first
antibody on AMeX-fixed A549 cells. Three days prior to cell
fusion, the animal with the highest titer was intra-peritoneally
boosted by the same amount of A549 lysate. Hybridoma
preparation and IHC screening with AMeX-fixed A549 cells
were previously described [4,5].
4. Proteomics analysis
4.1. Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE). Proteins were extracted from each of
A549, LC-2/ad, RERF-LC-AI, N231, and LCN1 cells with
detergent lysis buffer [16] using an ultra-sonic homogenizer. Ten
mg each of extracted proteins were boiled and separated by SDS-
PAGE with 10% polyacrylamide gel at a constant current of
20 mA. After SDS-PAGE, proteins in gels were transferred to a
polyvinylidene difluoride (PVDF) membrane (Millipore Corp.,
Billerica, MA, USA) for immunoblotting.
4.2. Immunoblotting. Blotting membranes were blocked
with 0.5% casein from bovine milk (Sigma, St. Louis, MO, USA)
for 30 min at RT. The membranes were then reacted with non-
Table 1. Clinicopathological characteristics of the patients.
Characteristics
Training set
(N=70)
Validation set
(N=26)
Age ,70 40 (57.1%) 19 (73.1%)
§70 30 (42.9%) 7 (26.9%)
Gender Male 52 (74.3%) 16 (61.5%)
Female 18 (25.7%) 10 (38.5%)
Stage I 19 (27.2%) 17 (65.4%)
II 11 (15.7%) 2 (7.7%)
III 26 (37.1%) 4 (15.4%)
IV 14 (20.0%) 3 (11.5%)
Tumor differentiation Well 7 (13.2%) 11 (52.4%)
(NSCLC) Moderate 10 (18.9%) 5 (23.8%)
Poor 18 (34.0%) 4 (19.0%)
Unknown 18 (34.0%) 1 (4.8%)
Tumor size ,3 cm 24 (34.3%) 15 (57.7%)
§3 cm 45 (64.3%) 6 (23.1)
Unknown 1 (1.4%) 5 (19.2)
Nodal status N0 23 (32.9%) 18 (69.3%)
N1 12 (17.1%) 1 (3.8%)
N2 23 (32.9%) 5 (19.2%)
N3 12 (17.1%) 2 (7.7%)
Distant metastasis M0 56 (80.0%) 23 (88.5%)
M1 14 (20.0%) 3 (11.5%)
Histological type AD
a 29 (41.4%) 20 (77.0%)
SCC
b 21 (30.0%) 0 (0.0%)
SCLC
c 17 (24.3%) 5 (19.2%)
LCNEC
d 3 (4.3%) 1 (3.8%)
aAdenocarcinoma.
bSquamous cell carcinoma.
cSmall cell lung carcinoma.
dLarge cell neuroendocrine carcinoma.
doi:10.1371/journal.pone.0033952.t001
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incubation with 1,000-times diluted horseradish peroxidase-
conjugated rabbit anti-mouse IgG polyclonal antibody (Dako,
Glostrup, Denmark) with 0.025% Casein for 45 min at RT.
Finally, signals were developed using Immobilon Western HRP
reagent (Millipore Corp.).
4.3. Determination of antibody isotype. To determine the
isotype of the established KU-Lu-5 antibody, we used the
IsoStrip
TM Mouse Monoclonal Antibody Isotyping Kit (Roche
Diagnostics, Mannheim, Germany) according to the manu-
facturer’s instructions.
4.4. Immunoprecipitation. The immunoprecipitation
method used in this study was previously described [17]. In brief,
A549 cells were washed with PBS (-) and treated with radio-
immunoprecipitation assay (RIPA) buffer containing Complete-
mini EDTA-free (Roche Diagnostics) on ice for 30 min. After
centrifugation at 15,000 rpm for 30 min at 4uC, the supernatant
was collected and precleared with protein G sepharose (50% slurry)
(GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) at 4uC
overnight. To conjugate the primary antibody, 250 mL of primary
antibody (KU-Lu-5 hybridoma supernatant) and 20 mL of protein
G sepharose beads suspended in RIPA buffer were incubated with
mixing at 4uC overnight. After centrifugation, the antibody-
sepharose conjugate and 500 mg of total cellular protein from the
precleared supernatant were incubated with mixing at 4uC for
4 hrs. The immunoprecipitates were collected by centrifugation at
15,000 rpm for 5 min at 4uC. After washing four times with RIPA
buffer, the supernatant was carefully removed and the pellets were
resuspended in 15 mLo f1 6Laemmili’s buffer. Then, 15 mLo f
samples were boiled and separated by SDS-PAGE with 10%
polyacrylamide gel. After SDS-PAGE, gels were Zn-stained with
theNegativeGel StainMSkit(WakoPureChemical,Tokyo,Japan)
according to the manufacturer’s instructions.
4.5. Identification of antigen protein. 4.5.1. In-gel digestion.
The protein spot was excised from the SDS-PAGE gel and minced
to 1 mm
3, destained with destaining solution (Wako Pure
Chemical), dehydrated with 100% (v/v) ACN, and dried under
vacuum conditions. Tryptic digestion was performed with a
minimal volume of digestion solution which contained 20 ng/mlo f
trypsin (Trypsin Gold, Mass Spectrometry Grade, Promega,
Madison, WI, USA) and 25 mM NH4HCO3 for 24 hrs at 37uC.
After incubation, digested protein fragments eluted in solution
were collected, and gels were washed once in 5% (v/v)
trifuloroacetic acid /50% (v/v) ACN and collected in the same
tube.
4.5.2. Protein identification. The collected peptide fragments were
analyzed using autoflex III matrix-associated laser desorption/
ionization-time of flight/time of flight mass spectrometry
(MALDI-TOF/TOF MS; Bruker Daltonik, Bremen, Germany).
A disposable plate, spotted a-cyano-4-hydroxycinnamic acid
matrix for samples, and PAC Peptide Calibstandard for
calibration (Prespotted AnchorChip 96 set for Proteomics, Bruker
Daltonik) were used. Peptide mass fingerprints (PMF) were
measured, and then a few peaks obtained from PMF were further
measured for their tandem mass spectra as parent masses.
MASCOT (http://www.matrixscience.com) using the IPI Human
database (93,289 sequences; 36,994,704 residues), released on 3
May, 2011 (http://www.matrixscience.com), was used to deter-
mine proteins from PMF and tandem mass data.
5. Immunoblot analysis with recombinant CAXII protein
Recombinant CAXII protein and Venus protein as a negative
control with GST-tag were prepared using a wheat germ cell-free
system [18]. Fourteen mg each of recombinant CAXII and Venus
proteins were boiled and separated with SDS-PAGE, followed by
immunoblotting with KU-Lu-5 antibody, as mentioned in 2.4.1.
6. Immunohistochemical staining
Three-mm-thick sections, made from 10% formalin-fixed and
paraffin-embedded lung cancer cell lines and 37 surgically resected
lung cancers (AD: 28, SCC: 9) were deparaffinized in xylene,
rehydrated in a descending ethanol series, and then treated with
3% hydrogen peroxide for 20 min. After the antigen was retrieved
by autoclaving in 0.01 mol/L citrate buffer (pH 6.0) with 0.1%
Tween 20 at 121uC for 10 min, the sections were reacted with
non-diluted KU-Lu-5 hybridoma supernatant for 16–18 hrs at
room temperature (RT). After rinsing in TBS three times for
5 min each, the sections were reacted with ChemMate Envision
reagent (Dako) for 30 min at RT. Finally, the sections were
visualized with Stable DAB solution (Invitrogen Corp.) and
counterstained with Mayer’s hematoxylin.
7. Dot blot analysis
7.1. Sample preparation. 7.1.1. Removal of albumin and IgG
from serum samples. The removal of albumin and IgG from sera was
performed using a ProteoExtract Albumin/IgG Removal kit
(Merck, Darmstadt, Germany) according to the manufacturer’s
instructions. A 60-mL sample of each sera was diluted with 540 mL
of binding buffer, and allowed to pass the column by gravity flow.
The flow-through fraction was collected in a collection tube. To
wash the column, binding buffer was allowed to pass the column
by gravity flow. The flow-through fraction was collected in the
same collection tube.
7.1.2. Desalting and concentration by ultrafiltration. The albumin- and
IgG-depleted samples were buffer-exchanged and concentrated
using 10-kDa molecular-weight cut-off ultra-filtration VIVASPIN
2 (Sartorius, Gottingen, Germany). The samples were centrifuged
at 6,0006ga t4 uC until less than 100 mL, and then the buffer was
exchanged for PBS (-) with concentration at 6,0006ga t4 uC until
concentrated to less than 50 mL. The concentrated samples were
adjusted to a final volume of 60 mL with PBS (-).
7.2. Dot blot analysis. One ml each of albumin- and IgG-
depleted samples diluted to 1:20 with PBS(-) and mouse IgG
(purified in our laboratory) for a positive control were spotted on a
PVDF membrane (Millipore Corp.) using the automatic dot blot
system with a 256-solid pin configuration (Kakengeneqs Inc.,
Chiba, Japan). Two sheets of membrane were prepared for one set
of experiment. Spotted membranes were washed in TBS for
10 min, and blocked with 0.5% casein (Sigma) for 1 hr at RT.
One membrane was then reacted with non-diluted KU-Lu-5
hybridoma supernatant, and the other membrane was reacted
with antibody diluting solution [20-times diluted 0.5% casein with
0.1% Tween 20 added TBS (TBS-T)] for 30 min at RT. After
rinsing in TBS-T 3 times for 5 min each, membranes were
incubated with 1,000-times diluted horseradish peroxidase-
conjugated rabbit anti-mouse IgG polyclonal antibody (Dako)
for 30 min at RT. Finally, signals were developed with Immobilon
Western reagent (Millipore Corp.). The data were analyzed using
DotBlotChipSystem Ver. 4.0 (Dynacom Co., Ltd., Chiba, Japan).
Each normalized signal was presented as the ratio of the positive
intensity versus the negative background intensity.
8. Statistical analysis
Serum CAXII levels in patients with lung cancer and healthy
controls were statistically analyzed using the Mann-Whitney U-
test. Sensitivity, specificity, and predictive values were calculated
with the SPBS software package (Ver. 9.42 for Windows) for each
variable at a corresponding cut-off. Discriminant function analysis
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‘‘healthy control’’ group, according to the status of the biomarkers,
using the SPBS software package. The area under the curve
(AUC) and best cut-off point were calculated employing receiver
operating characteristic (ROC) analysis. Results were considered
significant when P,0.05.
Results
1. Confirmation of antibody titer in mouse sera
The antibody titer was tested by IHC with 1,000-times diluted
sera of immunized mice as the first antibody on AMeX-fixed A549
cells. As a result, the sera from immunized mice contained
antibodies that reacted with various components of A549 cells.
Using AMeX-fixed A549 cell preparations for the immunohis-
tochemical screening of hybridomas, we finally established 188
MoAbs in total and a further study was performed with the KU-
Lu-5 clone, which showed intense staining in A549 cells (Fig. 1 A).
2. Identification of antigen protein
In order to identify the antigen protein recognized by the KU-
Lu-5 antibody, we performed IP with lysate from A549 cells. The
results of IP are shown in Fig. 1 B, C. The antigenic protein was
observed at roughly 40 kDa. To determine the antigenic protein
recognized by KU-Lu-5 antibody, we excised and collected the
spot from the Zn-stained gel, and proceeded with in-gel digestion.
After analysis employing a MALDI-TOF/TOF MS and a
MASCOT search, the protein was determined as isoform 2 of
carbonic anhydrase XII (CAXII, accession: IPI00221392), which
is composed of 343 amino acids with a predicted M.W. of 38,384
Da. The result was confirmed by immunoblot analysis with
recombinant CAXII protein using KU-Lu-5 hybridoma superna-
tant as the first antibody (Fig. 1 D). The immunoglobulin isotype
of KU-Lu-5 antibody was determined as IgG1, k.
3. Immunoblot analysis
Expression of CAXII was detected only in A549 cells as a
roughly 40-kDa protein, and no clear band was detected in other
cells used in this study (Fig. 2 A).
4. Immunohistochemical staining for CAXII
Immunohistochemically, membranous expression of CAXII
was observed only in A549 cells (Fig. 2 B). Membranous staining
was detected in 2 of the 28 ADs (7.1%) and in 2 of the 9 SCCs
(22.2%) (Fig. 2 C, D).
Figure 1. Production of anti-CAXII monoclonal antibody and its antigen identification. (A) The antibody titer was tested
immunohistochemically using 1,000-times diluted sera of immunized mice as the first antibody on AMeX-fixed A549 cells, which were used as an
immunogen. The sera of immunized mice contained antibodies that reacted with various cell components, such as the nucleus (q), plasma
membrane (m), and cytoplasm (qq). (B) Immunoprecipitation with KU-Lu-5 antibody. Immunoblot analysis using KU-Lu-5 hybridoma supernatant as
the first antibody [ lane 1: A549 lysate, lane 2: A549 lysate combined with protein G, lane 3: KU-Lu-5 antibody combined with protein G, lane 4: A549
lysate combined with KU-Lu-5 antibody]. Lanes 2 to 3 are negative controls, and immunoprecipitated product with KU-Lu-5 antibody was detected in
lane 4 (q). (C) Confirmation of identified antigen protein. KU-Lu-5 antibody reacted with recombinant CAXII protein (64 kDa), but not with
recombinant Venus protein.
doi:10.1371/journal.pone.0033952.g001
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The serum CAXII levels were significantly higher in lung cancer
patients than in healthy controls in the training set (P,0.0001).
Relative values of serum CAXII levels ranged from 0.101 to 4.01
(median: 1.520) in lung cancer patients, but 0.006 to 1.679 (median:
0.290) in healthy controls (Fig. 3 A). In lung cancer, CAXII serum
levels of SCC patients were significantly higher than those of AD
patients (P=0.03) (Fig. 3 A). The area under the ROC curve (AUC)
between lung cancers and healthy controls was 0.794 (Fig. 3 B).
When an optimal cut-off value of 0.387 for CAXII was applied, the
diagnostic sensitivity and specificity for lung cancer were 82.9 and
70.0, respectively, and the negative and positive predictive values
were 0.617 and 0.863, respectively. Furthermore, within SCCs,
serum CAXII levels were significantly higher in patients with well-
and moderately differentiated tumors than those with poorly
differentiated ones (P=0.027) (Fig. 4 A), and tended to be higher
inpatientswithatumorsizeoflessthan 3 cm ratherthan more than
3 cm (P=0.0538). However, there was no difference in the smoking
history of patients (Fig. 4 B). CAXII levels in stage I, II, and III ADs
were 1.501, 0.704, and 1.001, respectively, and CAXII levels in
stage I, II, and III SCCs were 1.764, 2.093, and 1.854, respectively.
These data were summarized in Table 2. No relations between the
CAXII serum levels and tumor stage or presence of metastasis were
identified for either ADs or SCCs. To further confirm the utility of
serum CAXII levels as a sero-diagnostic marker, 56 additional
samples of sera were analyzed by dot blot analysis as a validation
study.Theserum CAXIIlevelswere alsosignificantly higherinlung
cancer patients than in healthy controls in the validation set
(P=0.030). Relative values of serum CAXII levels ranged from
0.000 to 8.023 (median: 3.921) in lung cancer patients, but 0.000 to
8.331 (median: 2.806) in healthy controls (Fig. 5). When an optimal
cut-off value of 3.086 for applied, the diagnostic sensitivity and
specificity for lung cancer were 65.4 and 70.0, respectively.
Discussion
In this study, aiming to discover useful sero-diagnostic markers for
lung cancer, we generated monoclonal antibodies using lung AD-
derivedA549cellsasantigens.Fromtheobtained188antibodies,we
focused on an antibody recognizing CAXII, and explored its clinical
utility as a sero-diagnostic marker for lung cancer. This random
immunization method is expected to yield antibodies against tumor-
specific proteins with post-translational modifications, which are
difficult to obtain by conventional immunization methods. Actually,
several authors have reported that monoclonal antibodies generated
by this method are useful as diagnostic and prognostic markers for
cancers [5,17,19]. Battke et al. [20] established a 6A10 antibody
recognizing CAXII using a similar immunization methodology.
However,the obtained antibodieswerelimitedtothoseonlyreacting
with cell surface antigens because of using flow cytometry for the
screening of hybridomas. In the present study, the hybridomas were
immunohistochemically screened which facilitated the obtaining of
Figure 2. Expression of CAXII antibody in lung cancer cell lines and tissues. (A) Immunoblot analysis of CAXII in lung cancer cell lines. CAXII
was detected as an approximately 40-kDa protein with A549 cells. (B) Immunostaining of CAXII in A549 cells (a), adenocarcinoma (b), and squamous
cell carcinoma (c) of the lung, and each showed membranous staining of CAXII.
doi:10.1371/journal.pone.0033952.g002
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lung cancer and healthy controls. (A) The median CAXII level in the sera from healthy controls was 0.29, and that in sera from lung cancer patients
was 1.52. Serum CAXII levels were significantly higher in lung cancer patients (*P,0.001). Furthermore, serum CAXII levels were higher in SCCs than
ADs (**P=0.0381). (B) Receiver-operating characteristic curve analysis of CAXII as a serum marker for lung cancer. The corresponding areas under the
curves were 0.794 for CAXII. With a 70.0% specificity, the sensitivity of CAXII for lung cancer was 82.9%, at a cut-off value corresponding to 0.387.
doi:10.1371/journal.pone.0033952.g003
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several intra-cellular compartments. The CAs constitute a family of
ubiquitous enzymes with important roles in many physiological and
pathological processes which reversely catalyse the conversion of
CO2+H2Ot oH C O 3
2 and H
+, contributing to regulation of the
intracellular pH [6–11,19]. Several clinical studies have shown a
clear relationship between high CAXII expression levels in tumor
cells and a favorable prognosis.
Figure 4. Correlation between serum CAXII levels and patients’ clinicopathological characteristics. (A) CAXII levels in sera from patients
with ADs and SCCs with a focus on the stage and differentiation. In SCCs, CAXII levels were significantly higher in well- and moderately differentiated
tumors than in poorly differentiated ones (***P=0.0272). In ADs, no significant difference based on the differentiation extent was detected. (B)
Smoking history in lung cancer patients. The median CAXII level in the sera from non-smokers was 1.56, and that in smokers was 1.54, showing no
significant difference.
doi:10.1371/journal.pone.0033952.g004
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invasivebreastcarcinomacases,andwassignificantlyassociatedwith
a lower histological grade (P=0.001), positive estrogen receptor
status (P,0.01), and negative epidermal growth factor receptor
overexpression (P,0.001).Usingunivariateanalysis,CAXII-positive
tumors were associated with a lower relapse rate (P=0.04) and a
better OS (P=0.01). On the other hand, although 98% of
astrocytomas were immunohistochemically positive for CAXII,
higher CAXII expression levels were correlated with a higher
histological grade and a poorer patient outcome either by univariate
(P=0.010) or multivariate (P=0.039) survival analysis [9].
An immunohistochemical study of the expression of CAXII in lung
cancer was reported by Ilie et al. [13]. CAXII overexpression was
observed in 105/555 cases, and was significantly associated with a
better differentiation (P=0.015) and SCC histological type (P,0.001).
Furthermore, high CAXII expression was also significantly correlated
with better overall and disease-specific survival. From our results,
CAXII levels were higher in sera from SCC patients than ADs (Fig. 3
A). Also, they correlated more favorably with differentiation (Fig. 4 A).
Integrating these results, CAXII may not only be a candidate tissue
marker, but also a sero-diagnostic marker for lung cancer.
Although the association of CAXII expression and clinicopath-
ologic factors and patient outcome in different tumors has been
reported, to our knowledge, no study concerning the serum
CAXII protein levels or its autoantibody levels in patients with
tumors has been reported.
To confirm the possibility of CAXII as a sero-diagnostic
marker, we measured its serum levels in patients with lung cancer
and healthy controls. We demonstrated that the CAXII protein
flowed out into the sera and its levels in patients with lung cancer
were significantly higher than in healthy controls in both the
training set (P,0.0001) and validation set (P=0.030). It is possible
that the gap in the P-value between the training set and validation
set is caused by the fact that serum levels of CAXII of SCC
patients were generally higher than those of patients with other
histologies, and the validation set included no SCC case. Taken
together, the serum CAXII levels should be applicable markers
discriminating lung cancer patients from healthy controls.
Currently, CT scan or chest X-ray is the main method of lung
cancer screening [21]. Mazzone et al. suggested that blood and
breath tests should also be included for lung cancer screening,
because they are both easy to perform and free of risks related to
test administration [21,22]. In this study, we analyzed CAXII
levels in sera from lung cancer patients and healthy controls using
monoclonal antibody, and our results suggested that the serum
CAXII level was a useful sero-diagnostic marker for lung cancer.
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